Recent Updates
Recently added Catalysts

EQ504

Phase 1

Ulcerative Colitis | Small molecule | Gastrointestinal |Equillium, Inc.|Trials Updated: Oct 9, 2026

EQ504 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Oct 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials1
Total Enrollment70

FDA Designations

No designations recorded

EQ504 clinical trials

EQ504 · 1 trial · 1 indication

Phase 1 1
NCT07869225A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy VolunteersUlcerative Colitis
NOT YET_RECRUITING70 Analytics
PHASE1NOT YET_RECRUITING
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy Volunteers
Ulcerative Colitis
NCT0786922570
Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of Treatment Emergent Adverse Events
Part A up to Day 8, Part B up to Day 17, Part C up to Day 12

Number of participants with treatment-related adverse events

Secondary Endpoints

To characterize the PK of EQ504 - maximum observed plasma concentration (Cmax)
Part A through Day 4, Part B through Day 13, Part C through Day 8
To characterize the PK of EQ504 - time to maximum plasma concentration (Tmax)
Part A through Day 4, Part B through Day 13, Part C through Day 8
To characterize the PK of EQ504 - terminal elimination half-life (T 1/2)
Part A through Day 4, Part B through Day 13, Part C through Day 8
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
EQ504 Part AEXPERIMENTALEQ504 administered in a blinded dose escalating cohort fashion by oral administration once daily on Day 1.
EQ504 Part BEXPERIMENTALEQ504 administered in a blinded dose escalating cohort fashion by oral administration once daily on Days 1-10.
EQ504 Part CEXPERIMENTALEQ504 administered in a blinded fashion by oral administration once on Day 1 (fasted) and Day 5 (fed).
PlaceboPLACEBO_COMPARATORPlacebo administered in a blinded fashion by oral administration.

Interventions

NameTypeDescription
EQ504DRUGEQ504
EQ504 PlaceboDRUGPlacebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Males and females 18 to 65 years of age inclusive * Body mass index (BMI) 18 to 32 kg/m2, with a body weight greater than or equal to 55kg * Medically healthy without clinically significant abnormalities * Have suitable venous access for blood sampling Exclusion Criteria: * ...

Countries:Australia
Unlock Eligibility Criteria

Competitive Landscape -Ulcerative Colitis 121 trials

Top 20 of 23 competitors

CompanyTickerTrialsLead PhaseDrugs
Sanofi SA Sponsored ADRSNY8PHASE3Duvakitug, SAR442970, balinatunfib, SAR441566, Dupilumab
Eli Lilly and CompanyLLY8PHASE3Mirikizumab, Tirzepatide, Eltrekibart, MORF-057, LY4395089
AbbVie, Inc.ABBV15PHASE3Upadacitinib, Risankizumab, Lutikizumab, Adalimumab, Trosunilimab
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK10PHASE3Vedolizumab, Zasocitinib
Johnson & JohnsonJNJ21PHASE3Ustekinumab, Guselkumab, Golimumab, Infliximab, Icotrokinra
Merck & Co., Inc.MRK3PHASE3Tulisokibart, MK-8690
Pfizer Inc.PFE8PHASE3Etrasimod, tofacitinib
Gilead Sciences, Inc.GILD3PHASE3Filgotinib, Tilpisertib Fosmecarbil, emvistegrast
Abivax SA Sponsored ADRABVX2PHASE3ABX464
Bristol-Myers Squibb CompanyBMY5PHASE2Ozanimod
Hoffmann-La RocheRHHBY6PHASE3Afimkibart, RO7837195
Spyre Therapeutics, IncSYRE2PHASE2SPY001, SPY002, SPY003
AnaptysBio, Inc.ANAB1PHASE2Rosnilimab
Vanda Pharmaceuticals Inc.VNDA1PHASE3Ponesimod
GSK plc Sponsored ADRGSK3PHASE1GSK4528287, Aletekitug
Palatin Technologies, Inc.PTN1PHASE2PL8177
Xencor, Inc.XNCR1PHASE1XmAb942
Palisade Bio, Inc.PALI1PHASE2PALI-2108
Odyssey Therapeutics, Inc.ODTX1PHASE2OD-07656
Alamar Biosciences, Inc.ALMR1PHASE1ATTO-1091
Unlock Competitive Intelligence

Recent Changes (Last 90 Days)

LOWOct 9, 2026NCT07869225NEW_TRIAL: changed
LOWOct 9, 2026NCT07869225NEW_TRIAL: changed

Explore more on BiopharmaWatch

Equillium, Inc. (EQ)Pipeline, catalysts, financials, insiders and newsUlcerative Colitis disease mapEvery company developing for Ulcerative Colitis, by stage and capitalFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track